SEC Tracker
Get the app

Femasys FEMY

Femasys FY 2024: revenue $1.6M, up 52%; diluted EPS −$17.00

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Femasys reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$1.6M+52% from $1.1M in FY 202310-K income statement, on EDGAR
  2. Net income−$18.8MAgainst −$14.2M in FY 202310-K income statement, on EDGAR
  3. Diluted EPS−$17.00Against −$18.60 in FY 2023. Split-adjusted, as the tables show it; the filing reported −$0.8510-K income statement, on EDGAR
  4. Cash and cash equivalents$3.5M−84% from $21.7M in FY 202310-K balance sheet, on EDGAR
  5. Cash from operations−$19.4MAgainst −$11.3M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Femasys files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. DarioHealth DRIO public float $28M, Jun 30, 2025
  2. Cerenome CNSY public float $32M, Jun 30, 2025
  3. electroCore ECOR public float $28M, Jun 30, 2025
  4. QT Imaging Holdings QTI public float $33M, Jun 30, 2025
  5. Nephros NEPH public float $27M, Jun 30, 2025